TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Study to Evaluate the Effect of Embryonic Observation on the Gestation (PROdE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First cycle of ART treatment with conventional IVF or ICSI with donated eggs.~* Normal uterine cavity and a single or double embryo transfer, always performed on day 5 at blastocyst stage.~Exclusion Criteria:~* Patients above 50 years old, patients that were diagnosed with recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL) or uterine pathologies,~* Body mass index \>30 kg/m2.~* The use of seminal samples coming from donors or testicular origin.~* Cycles that included preimplantational genetic testing (PGT).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- No embryo observation (NEO) (Type: NO_INTERVENTION): Study group. No embryonic observation from day one to day five of embryo development.
- Embryo observation (EO) (Type: EXPERIMENTAL): Control group. Conventional embryonic observations performed in day two, three and five of embryo development.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does DNA Sperm Fragmentation Affects Embryo Morphokinetic?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 36 to 38 years~* Fresh sample semen~* Minimum 6 oocytes~* Semen sample with at least 5 million/ml and at least 30% of progressive motile sperm.~Exclusion Criteria:~* Patients younger than 36 or older than 38 years old~* Frozen semen sample~* Less tan 6 oocytes.~* Semen samples with less than 5 million / ml or less than 30% of motile sperm.

- Gender: ALL
- Minimum Age: 36 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- MACS (Type: EXPERIMENTAL): Patients with MACS Selection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients 18 to 45 years old with at least one diagnosed breast fibroadenoma~* Diagnosis of fibroadenoma must be based on:~  * clinical examination~ * ultrasound image alone for patients Under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. the BI-RADS score of this mammogram must be less than 3. In all cases where an uncertainly exists, the patient will not be included.~ * histological confirmation after core needle biopsy by two independant readers (biopsy must be performed at least two weeks before therapy unless a micro biopsy has been already done less than 3 months before inclusion visit and histopathology slices are available)~* the requirements for the distance from the skin and the following régions of the fibroadenoma are:~  * depth anterior edge \< 19.4mm~ * nodule thickness \> 7.3 mm~ * depth of posterior edge \> 12.5 mm~ * depth to rib cage \> 10mm~* patient's fibroadenoma size is greater to equal to 0.3 cc (measured by ultrasound on the day of the procedure)~* Lesions should be less than 20 mL~* The lesion must be sonographically visible~* Lesions presented during previous surveillance a minimum 20% increase volume AND/OR~* Patient are presenting a pain level \>= 3 as meaured on the VAS during the last 30 days AND/OR~* Patient are presenting a anxiety level \>= 3 as meaured on the VAS during the last 30 days before selection visit~* Fibroadenoma is palpable~* Patient candidate for sugery~* Patient has signed a written informed consent~* Patient with a social security coverage~Exclusion Criteria:~* Patient is pregnant or lactating~* Patient with history of laser or radiotherapy in the targeted breast~* Core biopsy diagnosis suggestive of cytosarcoma phyllodes tumor or other malignancy~* Patient with breast implant in the targeted breast~* Patient with predominantly liquid nodule~* Macro-calcifications in pre-focal HIFU path~* Nipple and or areola in pre-focal HIFU path~* Patient's fibroadenoma not clearly visible on the ultrasound images (in B-mode) at the inclusion visit~* Scars or moles before the focal point of the HIFU~* Patient participating in another clinical trial involving an investigational drug, or device

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Surgery (Type: ACTIVE_COMPARATOR): Surgery
- HIFU (Echopulse) (Type: ACTIVE_COMPARATOR): HIFU (Echopulse)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatically impaired subjects will be ≥18 years of age, have a diagnosis of liver cirrhosis and a MELD score of ≥19 at Screening. Note: At least 6 of the hepatically impaired subjects will have a MELD score of \>25.~Exclusion Criteria:~* Subject has known allergy to rifaximin, rifampin, or other rifamycins, excipients and/or vehicles used in the formulation, or any other clinically significant allergies.~* Subject has participated in an investigational drug or device study within 30 days prior to Day 1 (Baseline).~* Subject has any concurrent illness (other than liver cirrhosis), disability or circumstance that may affect the interpretation of clinical data, could cause noncompliance with treatment or visits or otherwise contraindicates participation in this study in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Rifaximin 550 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cord Milking Impacts Neurodevelopmental Outcomes in Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Expected delivery at \<32 week GA.~Exclusion Criteria:~* 1. Prenatal diagnosis of chromosomal or severe congenital malformations such as cyanotic congenital heart disease 2. Cord accidents such as ruptured Vasa Previa results in fetal blood loss, need for urgent delivery, placental abruption and cord prolapse 3. considered non-viable by attending neonatologist or obstetrician 4. Consent not granted

- Gender: ALL
- Minimum Age: None
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Cord Milking (Type: EXPERIMENTAL): The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
- Observational (Type: NO_INTERVENTION): Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Postoperative Sleep Study in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Breast cancer patients having a unilateral segmental mastectomy, with or without intraoperative lymph node mapping, sentinel node biopsy, and axillary node dissection~2. Ages \>= 40 years~3. American Society of Anesthesiology (ASA) physical status classification of preoperative functioning) 1-4 levels are acceptable~4. Willing and able to give written informed consent~5. Willing and able to complete questionnaires~6. Not currently taking benzodiazepine medication for insomnia.~Exclusion Criteria:~1. Autoimmune diseases: rheumatoid arthritis, systemic lupus, or other collagen vascular disease~2. Alcoholics~3. Seizure disorder~4. Thyroid disease~5. Pregnant or lactating patients (effects not known in pregnancy)~6. Renal/hepatic failure (if ood urea nitrogen (BUN) or creatinine (Cr) \>2.5\* Upper limit of normal (ULN); Bili or aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\>2.5\* ULN)~7. Dementia/poor compliance~8. Manic/psychotic patients~9. Children/adults under 40 yrs~10. Movement disorders (ex. restless leg syndrome)~11. Tremor disorder (ex. parkinsonism)~12. Chronic benzodiazepine use for sleep (\>4 times per week )~13. Designated preop medications including melatonin for sleep

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): 0.15 mg/kg capsules by mouth daily
- Placebo (Type: PLACEBO_COMPARATOR): Starch capsules by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 years or older,~* Presenting at least one of the following symptoms: spontaneous pain, burning sensation in eye, dysesthesia, allodynia, hyperalgesia~* French language-skills~Exclusion Criteria:~* Severe corneal or palpebral damage explaining current pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Phase 1b, Part 2 NSCLC Inclusion Criteria:~* Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable.~* Presence of one or more p53 mutations.~* Measurable disease using RECIST 1.1.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.~* Adequate hematological status.~* Adequate hepatic and renal function.~Phase 1b, Part 2 NSCLC Exclusion Criteria:~* Advanced NSCLC tumors with EGFR mutations or ALK re-arrangement or other actionable genetic aberrations for which an approved targeted treatment is available. Patients who received prior treatment with EGFR or ALK inhibitors or other systemic drugs or immunotherapy for NSCLC are not eligible.~* Patients who are candidates for anti-PD-1 monotherapy in 1st line advanced NSCLC (e.g. tumors with high PD-L1 expression).~* Presence of active central nervous system metastases and/or carcinomatous meningitis.~* Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.~Phase 1b, Part 1 SCLC Inclusion Criteria:~* Histopathological confirmation of ED SCLC that has recurred or been refractory to one line of treatment with standard platinum-based chemotherapy or immuno-chemotherapy. Patients who received immunotherapy after platinum-based chemotherapy are eligible.~* Presence of one or more p53 mutations.~* Measurable disease using RECIST 1.1.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~* Adequate hematological status.~* Adequate hepatic and renal function.~Phase 1b, Part 1 SCLC Exclusion Criteria:~* More than one line of prior chemotherapy for ED SCLC (prior immunotherapy is permitted, concurrent with or subsequent to first line chemotherapy).~* Presence of active central nervous system metastases and/or carcinomatous meningitis.~* Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed (Type: EXPERIMENTAL): None
- Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed (Type: EXPERIMENTAL): None
- Part 1 SCLC: ALRN-6924+Topotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Promethazine for Treatment of Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-65 years of age~* clinical diagnosis of diabetic gastroparesis.~* EGD without evidence of gastric outlet obstruction within the past five years~* gastric emptying scintigraphy test demonstrating \>10% solid food retention at 4 hours within the past three years.~Exclusion Criteria:~* the inability or unwillingness to provide informed consent~* currently pregnant or breast feeding~* prior placement of a gastric stimulator~* pyloric botulinum toxin injection within the past 12 months~* prior gastric surgery~* history of a connective tissue disorder~* use of narcotic medication within the past four weeks~* hemoglobin A1C \>12 mg/dL within the past 3 months~* current or recent (within past 4 weeks) use of promethazine, metoclopramide or domperidone~* hypersensitivity or prior adverse reaction to promethazine~* concomitant use of phenothiazines (i.e. prochlorperazine, chlorpromazine) or other agents likely to increase extrapyramidal reactions~* concomitant use of tiotropium or ipratropium~* narrow angle glaucoma~* urinary retention~* Parkinson's disease~* significant psychiatric disease~* history of seizure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Promethazine (Type: EXPERIMENTAL): Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo P.O. t.i.d. for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Noctura400 Treatment for Diabetic Retinopathy (CANDLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Subjects of either sex aged 18 years or over. ii. Diagnosis of diabetes mellitus (type 1 or type 2). iii. Presence of clinically significant centre-involving macular oedema resultant from DR of ≥400µm (CST/CMT as measured by OCT, and is listed for ranibizumab therapy in the study eye.~Exclusion Criteria:~Any potential participant will be excluded if they have:~i. Received any previous anti-VEGF/steroid intravitreal injections in the study eye in the last 6 months.~ii. Presence of proliferative diabetic retinopathy (PDR) at screening.~iii. Significant systemic diseases know to affect visual function, other than diabetes (e.g. Parkinson's disease or Alzheimer's disease).~iv. History of relevant sleeping disorders/insomnia .~v. A condition that would preclude participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard Arm (Type: ACTIVE_COMPARATOR): Those receiving only their prescribed ranibizumab treatment only
- Intervention Arm (Type: EXPERIMENTAL): Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton intrauterine pregnancy ≥20 weeks and ≤35 weeks gestational age~* Chief complaint of minor maternal trauma including motor vehicle accident, patient fall or assault with absence of maternal conditions outlined in exclusion criteria~Exclusion Criteria:~* Maternal shock~* Unstable vital signs~* Altered sensorium~* Head injury resulting in coma~* signs or symptoms of intraperitoneal bleeding~* Emergency laparotomy for fetal or maternal indications~* Bone fractures~* History of previous abruptio placenta~* Known or suspected placenta previa~* Rupture of membranes~* Multiple gestation~* Advanced cervical dilatation ≥3cm~* Non-reassuring fetal status requiring intervention~* Vaginal bleeding on presentation~* History of intercourse and/or digital vaginal exam and/or vaginal ultrasound ≤24 hours prior to presentation~* Illicit drug use

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 7 years followed in the 6 CRCM centers (Créteil, Marseille, Nantes, Toulouse, Clermont-Ferrand and Nice). We choose to enroll children aged 7 years or more because as they have a better adherence to nebulization treatment than younger children.~* Diagnosis of cystic fibrosis confirmed by sweat test (\>60mmol/L) and/or the identification of two CF-causing mutations~* Confirmed chronic rhinosinusitis by Ear Nose and Throat doctor by endoscopic examination: bilateral mucopurulent secretions at middle meatus present longer than 12 weeks with or without nasal polyps~* Positive bacteria susceptibility to tobramycin in samples from middle meatus~* Susceptibility of bacteria to tobramycin confirmed~* Pulmonary examination before enrollment~* Written informed consent obtained at enrollment for all patients (consent of minor's parent for children)~* Social security affiliation~Exclusion Criteria:~* - Oral antibiotic therapy one month before enrollment~* enrollment in another protocol with antibiotic~* Ongoing aerosolized tobramycin for endobronchial infection to avoid an overlap between treatment for lung and treatment for sinusitis~* Abnormal auditory acuity (decrease of 20dB in auditory acuity)~* Hypersensibility or allergenecity of aminoglycosides~* FEV \< 25% or FVC of 40% or more of the value predicted for height~* Transplant patient or patient on transplant list~* Patient under nasal oxygen or under noninvasive ventilation~* Pregnant woman~* Breast-feeding~* No Social security affiliation~* Informed consent non obtained at enrollment for all patients (consent of minor's parent for children)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin nebulized nasally (Type: EXPERIMENTAL): Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
- Physiologic serum nebulized nasally (Type: PLACEBO_COMPARATOR): Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues